3 Medical Tech Stocks Using AI to Defy a $1 Trillion Headwind

Medical information systems companies, including Doximity Inc., Veeva Systems Inc., and Omnicell, Inc., are harnessing generative AI, creating a distinct growth narrative that stands out in a healthcare market bracing for a nearly $1 trillion federal spending cut and a wave of drug patent expirations. While the broader sector faces significant structural pressures, these technology-focused firms are tapping into strong digital demand.

“We’re looking for early signs of a bottoming process, and we’re starting to see those green shoots,” Paul MacDonald, president at Harvest ETFs, told BNN Bloomberg in April, commenting on the surprising strength in the recent earnings season. For companies leveraging AI, those shoots may be growing faster, offering a clear path to efficiency and innovation as other parts of the sector contend with deep-rooted challenges.

The headwinds are substantial. A 2025 law is set to cut roughly $1 trillion in federal health spending over the next decade, primarily from Medicaid, according to the Congressional Budget Office. The CBO projects this will leave an additional 10 million Americans uninsured by 2034. Separately, a report from Evaluate cited by PharmaVoice indicates that nearly 200 branded drugs will lose patent protection by 2030, putting more than $300 billion in revenue at risk for pharmaceutical giants.

For investors, this creates a sharp divergence. While traditional providers and pharmaceutical companies face margin compression from reimbursement cuts and generic competition, technology firms using AI to automate workflows and deliver new data-driven services are positioned to capture a greater share of the sector’s value. This shifts the focus from broad sector-based investing to identifying specific companies riding the digital transformation wave.

The AI Safe Haven in a Strained Market

In a healthcare system grappling with rising costs and labor shortages, the efficiency gains promised by AI are becoming critical. Medical information systems companies like Doximity, Veeva, and Omnicell are at the center of this trend. They provide the digital infrastructure that manages everything from clinical trial data and patient records to pharmacy logistics and professional networking for physicians. By integrating generative AI, these platforms can enhance precision, reduce operational costs, and improve quality of care.

This mirrors a broader trend where AI is becoming a key differentiator for growth. In the design and surgical fields, companies like Autodesk and Intuitive Surgical are embedding AI to create stickier platforms and justify premium pricing, a strategy that is difficult for competitors to replicate. For the healthcare sector, which faces a potential wave of hospital closures and service cuts, this AI-driven efficiency is not just an advantage but a potential lifeline.

A Diverging Path for Healthcare Investors

The current environment is forcing a clear split in how investors must approach the healthcare sector. On one side are providers, such as HCA Healthcare, which are bellwethers for tracking the impact of rising uncompensated care costs and shrinking reimbursements. On the other are the technology enablers, who stand to benefit from the industry’s urgent need to do more with less.

The companies benefiting from AI adoption are not immune to market volatility, but their growth is tied to a powerful, long-term trend that runs counter to the sector's primary headwinds. As federal programs create new funding channels for telehealth and AI-powered tools, firms like Doximity, Veeva, and Omnicell find themselves in a narrow but meaningful lane for growth, even as the wider industry tightens its budgets. For investors, the key may no longer be betting on healthcare as a whole, but on the technology companies rewiring it for the future.

This article is for informational purposes only and does not constitute investment advice.